Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity

Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity

(2014) Fiona Errington et al.   JOURNAL OF IMMUNOLOGY

A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

(2008) L. Vidal et al.   CLINICAL CANCER RESEARCH

Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity

(2008) R. J. Prestwich et al.   CLINICAL CANCER RESEARCH

Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus

(2008) J. Qiao et al.   CLINICAL CANCER RESEARCH

Reovirus: Viral Therapy for Cancer ‘as Nature Intended’

(2008) C. Comins et al.   CLINICAL ONCOLOGY

Oncolytic viruses: a novel form of immunotherapy

(2008) Robin J Prestwich et al.   Expert Review of Anticancer Therapy

Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery

(2008) S H Thorne et al.   GENE THERAPY

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

(2008) C L White et al.   GENE THERAPY

Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

(2008) F Errington et al.   GENE THERAPY

Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors

(2008) J Qiao et al.   GENE THERAPY